Drug Type Small molecule drug |
Synonyms PLX 51107 |
Target |
Mechanism BRD4 inhibitors(Bromodomain-containing protein 4 inhibitors) |
Therapeutic Areas |
Inactive Indication |
Originator Organization |
Active Organization |
Inactive Organization |
Drug Highest PhasePhase 1 |
First Approval Date- |
Regulation- |
Molecular FormulaC26H22N4O3 |
InChIKeyAMSUHYUVOVCWTP-INIZCTEOSA-N |
CAS Registry1627929-55-8 |
Indication | Highest Phase | Country/Location | Organization | Date |
---|---|---|---|---|
Myelodysplastic-Myeloproliferative Diseases | Phase 1 | US | 09 Sep 2019 | |
Myeloproliferative Disorders | Phase 1 | US | 09 Sep 2019 | |
Acute Myeloid Leukemia | Phase 1 | US | 01 Mar 2016 | |
Myelodysplastic Syndromes | Phase 1 | US | 01 Mar 2016 | |
Non-Hodgkin Lymphoma | Phase 1 | US | 01 Mar 2016 | |
Solid tumor | Phase 1 | US | 01 Mar 2016 |
NCT04022785 (ASH2021) Manual | Phase 1 | 37 | PLX 51107+Azacitidine | jafzuetmmq(bugstdcmeo) = non-hema ~ logic ~ xicities: 9 (24%) pts had elevated bilirubin/liver function tests (n=2 Grade 4 and n=7 Grade 3) and n=24 had infections. opywnzdbri (gykezdaxat ) View more | Positive | 05 Nov 2021 | |
Phase 1/2 | 36 | puqieltbzf(srzfczlfwq) = 17% jglsofgkpn (biadnsykcv ) View more | - | 01 Jun 2018 |